The Europe peripheral liquid embolic agents market size was valued at USD 104.3 million in 2025 and is projected to grow from USD 109.4 million in 2026 to USD 178.6 million by 2036, at a CAGR of 5.0% from 2026 to 2036. The rising burden of peripheral artery disease and other vascular disorders is supporting demand for endovascular interventions. In addition, the growing preference for minimally invasive vascular procedures is contributing to the adoption of catheter-based treatment approaches due to lower procedural trauma, shorter hospital stays, and faster patient recovery.
The expansion of interventional radiology and vascular surgery services, together with improvements in catheter-based technologies and embolization techniques, is further supporting the use of liquid embolic agents in peripheral vascular procedures. An aging population and increasing healthcare focus on managing chronic vascular conditions are also expected to support demand for advanced peripheral embolization solutions across Europe.
For instance, the European Society of Cardiology’s (ESC) Cardiovascular Disease Statistics 2025 reports that 9.3 million new cardiovascular disease cases were recorded across ESC member countries in 2023, with peripheral arterial disease (PAD) accounting for 24% of new CVD cases. The report further estimates 121 million people living with CVD, while PAD prevalence represented 19% of people living with CVD, and PAD incidence reached 123.6 per 100,000 person-years. Among individuals aged 70 years and older, PAD incidence was substantially higher at 1,090 per 100,000 person-years, highlighting the significant vascular disease burden associated with population aging. These findings support demand for peripheral vascular interventions and advanced embolization technologies, including liquid embolic agents, as healthcare systems address the growing need for diagnosis and treatment of peripheral vascular disease.
In addition, the availability of specialized vascular centers, established endovascular treatment pathways, and growing expertise among vascular specialists are supporting the adoption of embolization procedures to treat aneurysm-related complications. Improvements in vascular imaging and surveillance following EVAR are enabling earlier identification and management of Type II endoleaks, increasing the utilization of peripheral liquid embolic agents. According to data published by the National Vascular Registry in 2025, when aneurysms develop in the aorta, they most frequently occur below the arteries supplying the kidneys and are known as infra-renal AAAs. The NVR received information on 2,511 people who had an elective repair of an unruptured infra-renal AAA in 2024, which corresponds to an estimated case-ascertainment rate for the UK of 91% (for England = 91%; for Wales = >100%; for Scotland = 64%; for NI = 100%)
The rising incidence and clinical diagnosis of varicocele in the UK are contributing to growth in the market by increasing demand for minimally invasive embolization procedures. Varicocele is one of the most common venous disorders affecting the male reproductive system. It is frequently associated with chronic scrotal pain, testicular dysfunction, and male infertility, prompting a growing number of patients to seek treatment. Transcatheter embolization has become an established therapeutic option for varicocele management, offering a minimally invasive alternative to surgical ligation. During the procedure, liquid embolic agents are used to achieve targeted occlusion of incompetent testicular veins, eliminate abnormal venous reflux, and preserve surrounding vascular structures.
The expansion of interventional radiology and vascular surgery services, together with improvements in catheter-based technologies and embolization techniques, is further supporting the use of liquid embolic agents in peripheral vascular procedures. An aging population and increasing healthcare focus on managing chronic vascular conditions are also expected to support demand for advanced peripheral embolization solutions across Europe.
For instance, the European Society of Cardiology’s (ESC) Cardiovascular Disease Statistics 2025 reports that 9.3 million new cardiovascular disease cases were recorded across ESC member countries in 2023, with peripheral arterial disease (PAD) accounting for 24% of new CVD cases. The report further estimates 121 million people living with CVD, while PAD prevalence represented 19% of people living with CVD, and PAD incidence reached 123.6 per 100,000 person-years. Among individuals aged 70 years and older, PAD incidence was substantially higher at 1,090 per 100,000 person-years, highlighting the significant vascular disease burden associated with population aging. These findings support demand for peripheral vascular interventions and advanced embolization technologies, including liquid embolic agents, as healthcare systems address the growing need for diagnosis and treatment of peripheral vascular disease.
In addition, the availability of specialized vascular centers, established endovascular treatment pathways, and growing expertise among vascular specialists are supporting the adoption of embolization procedures to treat aneurysm-related complications. Improvements in vascular imaging and surveillance following EVAR are enabling earlier identification and management of Type II endoleaks, increasing the utilization of peripheral liquid embolic agents. According to data published by the National Vascular Registry in 2025, when aneurysms develop in the aorta, they most frequently occur below the arteries supplying the kidneys and are known as infra-renal AAAs. The NVR received information on 2,511 people who had an elective repair of an unruptured infra-renal AAA in 2024, which corresponds to an estimated case-ascertainment rate for the UK of 91% (for England = 91%; for Wales = >100%; for Scotland = 64%; for NI = 100%)
The rising incidence and clinical diagnosis of varicocele in the UK are contributing to growth in the market by increasing demand for minimally invasive embolization procedures. Varicocele is one of the most common venous disorders affecting the male reproductive system. It is frequently associated with chronic scrotal pain, testicular dysfunction, and male infertility, prompting a growing number of patients to seek treatment. Transcatheter embolization has become an established therapeutic option for varicocele management, offering a minimally invasive alternative to surgical ligation. During the procedure, liquid embolic agents are used to achieve targeted occlusion of incompetent testicular veins, eliminate abnormal venous reflux, and preserve surrounding vascular structures.
Europe Peripheral Liquid Embolic Agents Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, the analyst has segmented the Europe peripheral liquid embolic agents market report based on product, application, end use, and country:Product Outlook (Revenue, USD Million, 2021 - 2036)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates / tissue glues combined
- n-butyl cyanoacrylate (n-BCA)
- n-hexyl cyanoacrylate (n-HCA)
- Others liquid embolics
Application Outlook (Revenue, USD Million, 2021 - 2036)
- Peripheral Vascular Hemorrhage
- Hypervascular Tumors
- Peripheral Vascular Malformations / AVMs
- Aneurysms / Pseudoaneurysms
- Type II Endoleaks
- Portal Vein Embolization (PVE)
- Venous Applications (varicocele, PCS, varicose veins)
- Other Peripheral Embolization Applications
End Use Outlook (Revenue, USD Million, 2021 - 2036)
- Hospitals
- Others
Country Outlook (Revenue, USD Million, 2021-2036)
- UK
- Germany
- France
- Italy
- Spain
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Europe Peripheral Liquid Embolic Agents Market Variables, Trends, & Scope
Chapter 4. Europe Peripheral Liquid Embolic Agents Market: Product Estimates & Trend Analysis
Chapter 5. Europe Peripheral Liquid Embolic Agents Market: Application Estimates & Trend Analysis
Chapter 6. Europe Peripheral Liquid Embolic Agents Market: End Use Estimates & Trend Analysis
Chapter 7. Europe Peripheral Liquid Embolic Agents Market: Regional Estimates & Trend Analysis by Product, Application, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- BALT Group
- GEM S.r.l. (H.B. Fuller)
- Terumo Medical Corporation (MicroVention)
- B. Braun SE
- Qmedics
- NeuroSafe Medical / Sirtex Medical
- Johnson & Johnson MedTech (Cordis)
- Peters Surgical
- Boston Scientific Corporation
- BlackSwan Vascular / Sirtex Medical
